News

Back

Rokote Laboratories selects Exothera for GMP manufacturing of its second-generation coronavirus vaccine FINCoVac 2.0

March 31st 2022

BSCB Dev

Rokote Laboratories Finland Ltd., a vaccine development company focussing on a second-generation COVID-19 vaccine, and Exothera S.A. will collaborate to bring the intranasal coronavirus vaccine FINCoVac 2.0 to clinical Phase I/II trials. Exothera will finetune the industrialization of the FINCOVAC 2.0 process and manufacture clinical material for Phase I/II trials.

Read Pdf